Drug intelligence / Profile preview

Ad26.Filo

Development stage: Phase 1
Lead developer: Janssen Pharmaceutical
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Ad26.Filo is an investigational trivalent prophylactic **adenovirus serotype 26 viral-vector vaccine** for filovirus diseases. It is a fixed 1:1:1 mixture of three recombinant, replication-incompetent Ad26-vectored vaccine components: Ad26.ZEBOV, encoding the glycoprotein of Zaire ebolavirus Mayinga; Ad26.SUDV, encoding the glycoprotein of Sudan virus Gulu; and Ad26.MARV, encoding the glycoprotein of Marburg virus Angola. By delivering these glycoprotein antigens in vivo, the vaccine is intended to elicit antigen-specific humoral and cellular immune responses against Ebola virus disease, Sudan virus disease, and Marburg virus disease. Janssen evaluated Ad26.Filo in a completed Phase 1 heterologous prime-boost study with MVA-BN-Filo in healthy adults.

Other names: Ad26 multivalent filovirus vaccineAd-26 multivalent filovirus vaccineAd 26 multivalent filovirus vaccineAd26.Filo multivalent vaccineAd-26.Filo multivalent vaccineAd 26.Filo multivalent vaccine

Targets

PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on Ad26.Filo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad26.Filo.

Explore the full profile